TherapeuticsMD, Inc. (29TA.SG)
| Previous close | 4.7000 |
| Open | 4.6000 |
| Bid | 4.8400 x N/A |
| Ask | 5.0500 x N/A |
| Day's range | 4.6000 - 4.7400 |
| 52-week range | 1.9424 - 19.9000 |
| Volume | |
| Avg. volume | 306 |
| Market cap | 46.414M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 Mar 2023 - 13 Mar 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma
BOCA RATON, Fla., January 03, 2023--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has completed its previously announced transaction with Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, pursuant to which TXMD granted Mayne Pharma an exclusive license to commercialize TXMD’s products
- Business Wire
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
BOCA RATON, Fla., December 04, 2022--TherapeuticsMD, Inc. (NASDAQ: TXMD) ("TherapeuticsMD," "TXMD" or the "Company"), an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne Pharma Group Limited ("Mayne Pharma"), an ASX-listed specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals, for commercialization in the United States. In addition, TXMD has agree
- Zacks
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
TherapeuticsMD (TXMD) delivered earnings and revenue surprises of -53.43% and 30.74%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
